Pooja P. Mallya

Letermovir prophylaxis in pediatric haploidentical TCR αβ-depleted transplants: real-world outcomes in a low and middle-income country

Sunil Bhat, Pooja P. Mallya, Niveditha S. Reddy, Shreyas A C et autres

in (code pays fourni par la source)

Varnimcabtagene autoleucel in relapsed or refractory B-cell malignancies

Sharat Damodar, Sunil Jee Bhat, Raja Thirumalairaj, Pankaj Malhotra et autres

Varnimcabtagene autoleucel (varnim-cel), an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy, has demonstrated an antitumor activity and toxicity profile consistent with known CAR T-cell–associated adverse effects in patients with relapsed or refractory B-cell malignancies, including B-cell acute lymphoblastic leukemia (B-ALL) and …

Long-Term Safety and Efficacy Outcomes of Varnimcabtagene Autoleucel in Relapsed Refractory B Cell Malignancies: India Phase 2 Imagine Study

Sharat Damodar, Sunil Jee Bhat, Raja Thirumalairaj, Pankaj Malhotra et autres

Introduction Varnimcabtagene autoleucel (IMN-003A) is an autologous CD19-targeted CAR T-cell product with 4-1BB co-stim domain and A3B1 murine scFv, manufactured in India. Here, we present long-term outcomes from IMAGINE, a Phase 2, multicenter, single-arm study in patients with relapsed/refractory B cell malignancies …

in (code pays fourni par la source)

Pericardial Effusion Post Hematopoietic Stem Cell Transplant: A Life-Threatening Complication with Myriad Causes

Sidharth Totadri, Shobha Badiger, Pooja P. Mallya, Ravi Joshi et autres

in (code pays fourni par la source)

Hypogammaglobulinemia and Infection Risk in Relapsed Refractory B Cell Malignancy Patients Treated with Varnimcabtagene Autoleucel (IMN-003A), a CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy, in the Phase-2 Study (IMAGINE)

Sharat Damodar, Sunil Bhat, Raja Thirumalairaj, Pankaj Malhotra et autres

Background: Varnimcabtagene autoleucel (IMN-003A) is an anti-CD19 CAR-T cell immunotherapy for patients with relapsed refractory B cell malignancies (RR BCM) in the Phase 2 IMAGINE study. Hypogammaglobinemia can result from normal CD19+ B cell depletion (on-target, off-site effect) by CD19 directed CAR-T …

in (code pays fourni par la source)

Varnimcabtagene Autoleucel (IMN-003A): Pharmacokinetic Profile with Predominant Naïve and Central Memory Phenotype Demonstrates Sustained In Vivo Persistence and Durable Responses in a First-in-India Industry Phase-2 Study (IMAGINE)

Sunil Bhat, Sharat Damodar, Raja Thirumalairaj, Pankaj Malhotra et autres

Background: Varnimcabtagene autoleucel (IMN-003A) is an autologous CD19 directed CAR-T cell product with a 4-1BB co-stimulatory domain and a non-FMC63 murine single chain variable fragment (A3B1 binder), manufactured in India, tested in the IMAGINE study (CTRI/2022/03/041162), a phase-2 clinical trial for patients …

in (code pays fourni par la source)

Factors Associated with Refractoriness or Relapse after Varnimcabtagene Autoleucel (IMN-003A) in Patients with Relapsed Refractory B Cell Malignancies: Phase 2 First-in-India Industry (IMAGINE) Study

Sharat Damodar, Sunil Bhat, Raja Thirumalairaj, Pankaj Malhotra et autres

Background: Varnimcabtagene autoleucel (IMN-003A) is an anti-CD19 CAR-T cell immunotherapy for patients with relapsed refractory B cell malignancies (RR BCM) in the Phase 2 IMAGINE study. Some patients (pts) do not respond or relapse early after CD19 directed CAR-T cell therapy. This …

in (code pays fourni par la source)

Modified Endothelial Activation and Stress Index (mEASIX) Score and Immune Effector Cell Associated Haematotoxicity (ICAHT) Following Varnimcabtagene Autoleucel (IMN-003A), a CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy, in the Phase-2 Study (IMAGINE)

Sunil Bhat, Sharat Damodar, Raja Thirumalairaj, Pankaj Malhotra et autres

Background: Varnimcabtagene autoleucel (IMN-003A) is an anti-CD19 CAR-T cell immunotherapy for patients (pts) with relapsed refractory B cell malignancies (RR BCM) in first-in-India Industry Phase 2 IMAGINE study, administered in a fractionated (10%/30%/60%) infusion protocol. Cytokine Release Syndrome (CRS) and Immune Effector …

in (code pays fourni par la source)

Primary Analysis of Varnimcabtagene Autoleucel (IMN-003A) in Phase 2 Study (IMAGINE), a First-in-India Industry CD19-Directed CAR-T Cell Therapy for Patients with Relapsed Refractory B Cell Malignancies

Sharat Damodar, Sunil Jee Bhat, Raja Thirumalairaj, Pankaj Malhotra et autres

Background: Varnimcabtagene autoleucel (IMN-003A) is an autologous second-generation CAR-T cell product with a 4-1BB co-stimulatory domain and a non-FMC63 based murine single chain variable fragment targeting CD19 (A3B1 binder), manufactured in India. Preclinical and Phase 1 study was conducted at HCB / …

in (code pays fourni par la source)

P1364: PHARMACOKINETIC PROFILE OF VARNIMCABTAGENE AUTOLEUCEL (IMN-003A), FIRST-IN-INDIA INDUSTRY CD19-DIRECTED CAR-T CELL THERAPY FOR PATIENTS WITH RELAPSED/ REFRACTORY B CELL MALIGNANCIES (IMAGINE STUDY)

Pankaj Malhotra, Sunil Bhat, Sharat Damodar, Raja Thirumalairaj et autres

Topic: 24. Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Research Background: Varnimcabtagene autoleucel (IMN-003A) is an autologous CD19 directed CAR-T cell product with a 4-1BB co-stimulatory domain and A3B1 binder, a non-FMC63 murine single chain variable fragment, manufactured in …

in (code pays fourni par la source)

P1409: PHASE-2 STUDY OF VARNIMCABTAGENE AUTOLEUCEL (IMN-003A) FIRST-IN-INDIA INDUSTRY CD19-DIRECTED CAR-T WITH FRACTIONATED INFUSIONS FOR PATIENTS WITH RELAPSED REFRACTORY B CELL MALIGNANCIES: IMAGINE STUDY

Pankaj Malhotra, Sharat Damodar, Sunil Bhat, Raja Thirumalairaj et autres

Topic: 25. Gene therapy, cellular immunotherapy and vaccination - Clinical Background: Varnimcabtagene autoleucel (IMN-003A) is an autologous second-generation CAR-T cell product with a 4-1BB domain and A3B1 binder, non-FMC63 based murine single chain variable fragment targeting CD19, manufactured in India. Pre-clinical studies …

in (code pays fourni par la source)

Pericardial effusion post hematopoietic stem cell transplant: A life-threatening complication with myriad causes

Sidharth Totadri, Shobha Badiger, Pooja P. Mallya, Ravi Joshi et autres

in (code pays fourni par la source)